Videos Library

Adaptive, Umbrella and Basket studies - What are they, Why are they needed, and how will payers receive them?

Related topics: Pharmaceutical/Biotech, Market Access & HEOR

This free video is available for registered users


There is a well-recognized long-standing decline in R&D productivity in the pharmaceutical industry which has driven exploration of new approaches to the clinical development of pharmaceuticals.  These include innovative randomized controlled trial designs, including adaptive, umbrella, and basket studies. Adaptive trials, perhaps the best established of these, have already been the subject of guidance documents by both the European Medicines Agency and Food and Drug Administration. However, in many markets it is the reimbursement hurdle (rather than the regulatory hurdle) that is proving the major barrier to overcome in order to enable patient access. Therefore, payer perceptions on such innovative trial designs will be key to informing pharmaceutical company utilization of such approaches. This presentation will provide an overview of these innovative new designs and present payer perspectives on the benefits and challenges posed by conducting reimbursement assessments on data coming from these trial designs, based on discussions with a German and UK payer.


Janice Haigh
VP Pricing & Market Access
Parexel Access Consulting


Richard Macaulay
Principal Consultant, (Pricing and Market Access)
Parexel, UK


Subscribe or unlock this video to download the presentation slides. If you already have an account, please log in.


This is the presenters’ personal opinion and does not necessarily represent true facts, the official views or policy of their organisation, nor the views of NextLevel Life Sciences.